These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28427285)

  • 21. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen levels, emotion regulation, and emotional symptoms of women with premenstrual dysphoric disorder: The moderating effect of estrogen receptor 1α polymorphism.
    Yen JY; Wang PW; Su CH; Liu TL; Long CY; Ko CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():216-223. PubMed ID: 29146473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
    Freeman EW; Sondheimer SJ; Rickels K
    Psychopharmacol Bull; 1997; 33(2):303-9. PubMed ID: 9230648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The late-luteal leptin level, caloric intake and eating behaviors among women with premenstrual dysphoric disorder.
    Ko CH; Yen CF; Long CY; Kuo YT; Chen CS; Yen JY
    Psychoneuroendocrinology; 2015 Jun; 56():52-61. PubMed ID: 25800149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial.
    Brown CS; Ling FW; Andersen RN; Farmer RG; Arheart KL
    Obstet Gynecol; 1994 Nov; 84(5):779-86. PubMed ID: 7936512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered estradiol-dependent cellular Ca
    Li HJ; Goff A; Rudzinskas SA; Jung Y; Dubey N; Hoffman J; Hipolito D; Mazzu M; Rubinow DR; Schmidt PJ; Goldman D
    Mol Psychiatry; 2021 Nov; 26(11):6963-6974. PubMed ID: 34035477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli.
    Gingnell M; Bannbers E; Wikström J; Fredrikson M; Sundström-Poromaa I
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1474-83. PubMed ID: 24001875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mid-Luteal Progesterone Is Inversely Associated with Premenstrual Food Cravings.
    Hamidovic A; Soumare F; Naveed A; Davis J
    Nutrients; 2023 Feb; 15(5):. PubMed ID: 36904096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What's Stopping Us? Using GnRH Analogs With Stable Hormone Addback in Treatment-Resistant Premenstrual Dysphoric Disorder: Practical Guidelines and Risk-Benefit Analysis for Long-term Therapy.
    Wagner-Schuman M; Kania A; Barone JC; Ross JM; Mulvihill A; Eisenlohr-Moul TA
    J Clin Psychiatry; 2023 Jun; 84(4):. PubMed ID: 37341478
    [No Abstract]   [Full Text] [Related]  

  • 30. [Premenstrual syndrome and premenstrual dysphoric disorder-Overview on pathophysiology, diagnostics and treatment].
    Haußmann J; Goeckenjan M; Haußmann R; Wimberger P
    Nervenarzt; 2024 Mar; 95(3):268-274. PubMed ID: 38393358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limbic self-neuromodulation as a novel treatment option for emotional dysregulation in premenstrual dysphoric disorder (PMDD); a proof-of-concept study.
    Tene O; Bleich Cohen M; Helpman L; Fine N; Halevy A; Goldway N; Perry D; Bary P; Aisenberg Romano G; Ben-Zion Z; Hendler T; Bloch M
    Psychiatry Clin Neurosci; 2023 Oct; 77(10):550-558. PubMed ID: 37354437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stress, mood, and cortisol during daily life in women with Premenstrual Dysphoric Disorder (PMDD).
    Beddig T; Reinhard I; Kuehner C
    Psychoneuroendocrinology; 2019 Nov; 109():104372. PubMed ID: 31357135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grey matter morphology in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
    Kaltsouni E; Dubol M; Wikström J; Lanzenberger R; Sundström-Poromaa I; Comasco E
    Eur Neuropsychopharmacol; 2022 Dec; 65():35-43. PubMed ID: 36343426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nociceptive processing in women with premenstrual dysphoric disorder (PMDD): the role of menstrual phase and sex hormones.
    Bartley EJ; Palit S; Kuhn BL; Kerr KL; Terry EL; DelVentura JL; Rhudy JL
    Clin J Pain; 2015 Apr; 31(4):304-14. PubMed ID: 24810651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback.
    Schmidt PJ; Keenan PA; Schenkel LA; Berlin K; Gibson C; Rubinow DR
    Arch Womens Ment Health; 2013 Feb; 16(1):47-58. PubMed ID: 23188540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
    Kaltsouni E; Fisher PM; Dubol M; Hustad S; Lanzenberger R; Frokjaer VG; Wikström J; Comasco E; Sundström-Poromaa I
    Neuropsychopharmacology; 2021 Jul; 46(8):1460-1467. PubMed ID: 33927343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic intersection of BDNF Val66Met genotype with premenstrual dysphoric disorder transcriptome in a cross-species model of estradiol add-back.
    Marrocco J; Einhorn NR; Petty GH; Li H; Dubey N; Hoffman J; Berman KF; Goldman D; Lee FS; Schmidt PJ; McEwen BS
    Mol Psychiatry; 2020 Mar; 25(3):572-583. PubMed ID: 30356121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot Data on the Feasibility And Clinical Outcomes of a Nomegestrol Acetate Oral Contraceptive Pill in Women With Premenstrual Dysphoric Disorder.
    Robertson E; Thew C; Thomas N; Karimi L; Kulkarni J
    Front Endocrinol (Lausanne); 2021; 12():704488. PubMed ID: 34630323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A forced swim-based rat model of premenstrual depression: effects of hormonal changes and drug intervention.
    Wei S; Geng X; Li Z; Xu K; Hu M; Wu H; Shi W; Qiao M
    Aging (Albany NY); 2020 Nov; 12(23):24357-24370. PubMed ID: 33229622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.